TransCode Therapeutics Ownership 2024 | Who Owns TransCode Therapeutics Now?

Overview RevenueFinancials Chart

Institutional Ownership

0.09%

Insider Ownership

0.05%

Retail Ownership

99.86%

Institutional Holders

11.00

TransCode Therapeutics Institutional Shareholders

Institutional Shareholders by % of Total Shares

Name	% Total Shares	% Total Assets	Current Shares	Change Amount	Change %	Market Value	Date
WELLS FARGO & COMPANY/MN	-	-	-	-51	-100.00%	-	Jun 30, 2023
STATE STREET CORP	-	-	-	-21,019	-100.00%	-	Jun 30, 2023
GOLDMAN SACHS GROUP INC	-	-	-	-13,122	-100.00%	-	Jun 30, 2023
SHEETS SMITH WEALTH MANAGEMENT	-	-	-	-60,000	-100.00%	-	Jun 30, 2023
TWO SIGMA INVESTMENTS, LP	-	-	-	-19,407	-100.00%	-	Jun 30, 2023
GEODE CAPITAL MANAGEMENT, LLC	-	-	-	-75,683	-100.00%	-	Jun 30, 2023
BLACKROCK INC.	-	-	-	-1,385	-100.00%	-	Jun 30, 2023
TOWER RESEARCH CAPITAL LLC (TRC)	-	-	-	-6,351	-100.00%	-	Jun 30, 2023
WARBERG ASSET MANAGEMENT LLC	-	-	-	-20,000	-100.00%	-	Jun 30, 2023
SHAY CAPITAL LLC	-	-	-	-15,060	-100.00%	-	Jun 30, 2023
ONE68 GLOBAL CAPITAL, LLC	-	-	-	-30,120	-100.00%	-	Jun 30, 2023

TransCode Therapeutics's largest institutional shareholder is WELLS FARGO & COMPANY/MN, holding 0.00% of the company's total share outstanding, currently valued at -. The top 10 institutional shareholders own together 0.00% of the company.

Institutional Shareholders by % of Total Assets

Name	% Total Shares	% Total Assets	Current Shares	Change Amount	Change %	Market Value	Date
WELLS FARGO & COMPANY/MN	-	-	-	-51	-100.00%	-	Jun 30, 2023
STATE STREET CORP	-	-	-	-21,019	-100.00%	-	Jun 30, 2023
GOLDMAN SACHS GROUP INC	-	-	-	-13,122	-100.00%	-	Jun 30, 2023
SHEETS SMITH WEALTH MANAGEMENT	-	-	-	-60,000	-100.00%	-	Jun 30, 2023
TWO SIGMA INVESTMENTS, LP	-	-	-	-19,407	-100.00%	-	Jun 30, 2023
GEODE CAPITAL MANAGEMENT, LLC	-	-	-	-75,683	-100.00%	-	Jun 30, 2023
BLACKROCK INC.	-	-	-	-1,385	-100.00%	-	Jun 30, 2023
TOWER RESEARCH CAPITAL LLC (TRC)	-	-	-	-6,351	-100.00%	-	Jun 30, 2023
WARBERG ASSET MANAGEMENT LLC	-	-	-	-20,000	-100.00%	-	Jun 30, 2023
SHAY CAPITAL LLC	-	-	-	-15,060	-100.00%	-	Jun 30, 2023
ONE68 GLOBAL CAPITAL, LLC	-	-	-	-30,120	-100.00%	-	Jun 30, 2023

The largest TransCode Therapeutics shareholder by % of total assets is WELLS FARGO & COMPANY/MN. The company owns 0.00 shares of TransCode Therapeutics (RNAZ), representing 0.00% of its total assets.

Institutional Buyers

Name	% Total Shares	% Total Assets	Current Shares	Change Amount	Change %	Market Value	Date
WELLS FARGO & COMPANY/MN	-	-	-	-51	-100.00%	-	Jun 30, 2023
BLACKROCK INC.	-	-	-	-1,385	-100.00%	-	Jun 30, 2023
TOWER RESEARCH CAPITAL LLC (TRC)	-	-	-	-6,351	-100.00%	-	Jun 30, 2023
GOLDMAN SACHS GROUP INC	-	-	-	-13,122	-100.00%	-	Jun 30, 2023
SHAY CAPITAL LLC	-	-	-	-15,060	-100.00%	-	Jun 30, 2023
TWO SIGMA INVESTMENTS, LP	-	-	-	-19,407	-100.00%	-	Jun 30, 2023
WARBERG ASSET MANAGEMENT LLC	-	-	-	-20,000	-100.00%	-	Jun 30, 2023
STATE STREET CORP	-	-	-	-21,019	-100.00%	-	Jun 30, 2023
ONE68 GLOBAL CAPITAL, LLC	-	-	-	-30,120	-100.00%	-	Jun 30, 2023
SHEETS SMITH WEALTH MANAGEMENT	-	-	-	-60,000	-100.00%	-	Jun 30, 2023
GEODE CAPITAL MANAGEMENT, LLC	-	-	-	-75,683	-100.00%	-	Jun 30, 2023

As of Jun 30 2023, TransCode Therapeutics's largest institutional buyer is WELLS FARGO & COMPANY/MN. The company purchased -51.00 stocks of RNAZ, valued at -.

Institutional Sellers

Name	% Total Shares	% Total Assets	Current Shares	Change Amount	Change %	Market Value	Date
GEODE CAPITAL MANAGEMENT, LLC	-	-	-	-75,683	-100.00%	-	Jun 30, 2023
SHEETS SMITH WEALTH MANAGEMENT	-	-	-	-60,000	-100.00%	-	Jun 30, 2023
ONE68 GLOBAL CAPITAL, LLC	-	-	-	-30,120	-100.00%	-	Jun 30, 2023
STATE STREET CORP	-	-	-	-21,019	-100.00%	-	Jun 30, 2023
WARBERG ASSET MANAGEMENT LLC	-	-	-	-20,000	-100.00%	-	Jun 30, 2023
TWO SIGMA INVESTMENTS, LP	-	-	-	-19,407	-100.00%	-	Jun 30, 2023
SHAY CAPITAL LLC	-	-	-	-15,060	-100.00%	-	Jun 30, 2023
GOLDMAN SACHS GROUP INC	-	-	-	-13,122	-100.00%	-	Jun 30, 2023
TOWER RESEARCH CAPITAL LLC (TRC)	-	-	-	-6,351	-100.00%	-	Jun 30, 2023
BLACKROCK INC.	-	-	-	-1,385	-100.00%	-	Jun 30, 2023
WELLS FARGO & COMPANY/MN	-	-	-	-51	-100.00%	-	Jun 30, 2023

As of Jun 30 2023, TransCode Therapeutics's biggest institutional seller is GEODE CAPITAL MANAGEMENT, LLC. The company sold -75.68K shares of RNAZ, valued at -.

Institutional New positions

Name	% Total Shares	% Total Assets	Current Shares	Change Amount	Change %	Market Value	Date

Institutional Sold Out

Name	% Total Shares	% Total Assets	Current Shares	Change Amount	Change %	Market Value	Date
GEODE CAPITAL MANAGEMENT, LLC	-	-	-	-75,683	-100.00%	-	Jun 30, 2023
SHEETS SMITH WEALTH MANAGEMENT	-	-	-	-60,000	-100.00%	-	Jun 30, 2023
ONE68 GLOBAL CAPITAL, LLC	-	-	-	-30,120	-100.00%	-	Jun 30, 2023
STATE STREET CORP	-	-	-	-21,019	-100.00%	-	Jun 30, 2023
WARBERG ASSET MANAGEMENT LLC	-	-	-	-20,000	-100.00%	-	Jun 30, 2023
TWO SIGMA INVESTMENTS, LP	-	-	-	-19,407	-100.00%	-	Jun 30, 2023
SHAY CAPITAL LLC	-	-	-	-15,060	-100.00%	-	Jun 30, 2023
GOLDMAN SACHS GROUP INC	-	-	-	-13,122	-100.00%	-	Jun 30, 2023
TOWER RESEARCH CAPITAL LLC (TRC)	-	-	-	-6,351	-100.00%	-	Jun 30, 2023
BLACKROCK INC.	-	-	-	-1,385	-100.00%	-	Jun 30, 2023
WELLS FARGO & COMPANY/MN	-	-	-	-51	-100.00%	-	Jun 30, 2023

TransCode Therapeutics's largest sold out institutional shareholder by shares sold is GEODE CAPITAL MANAGEMENT, LLC, sold -75.68K shares, valued at -, as of undefined.

TransCode Therapeutics Mutual Fund Holders

Name	% Total Assets	Total Shares	Change Amount	Change %	Date
VANGUARD INDEX FUNDS	0.00%	200,117	-	-	Mar 31, 2024
FIDELITY CONCORD STREET TRUST	0.00%	74,374	-	-	Feb 29, 2024
FIDELITY CONCORD STREET TRUST	0.00%	52,326	-	-	Feb 29, 2024
USAA MUTUAL FUNDS TRUST	0.00%	1,131	-	-	Jan 31, 2024
EQ ADVISORS TRUST	0.00%	1,385	-	-	Mar 31, 2024
iSHARES TRUST	0.00%	14,293	-	-	Mar 31, 2024

TransCode Therapeutics's largest mutual fund holder by % of total assets is "VANGUARD INDEX FUNDS", owning 200.12K shares, compromising 0.00% of its total assets.

TransCode Therapeutics Institutional Ownership Trends

Institutional Holdings Trend

Date	Holdings	Change %
31 Mar, 23	11	-38.89%
31 Dec, 22	18	63.64%
30 Sep, 22	11	-8.33%
30 Jun, 22	12	-
31 Mar, 22	12	-14.29%
31 Dec, 21	14	-12.50%
30 Sep, 21	16	-

As of 31 Mar 23, 11 institutions are holding TransCode Therapeutics's shares, representing a decrease of -38.89% compared to the previous quarter.

Shares Outstanding Trend

Date	Shares Outstanding	Change %
31 Mar, 23	262,198	-24.05%
31 Dec, 22	345,210	-83.28%
30 Sep, 22	2,064,102	-0.99%
30 Jun, 22	2,084,804	91.33%
31 Mar, 22	1,089,616	-53.71%
31 Dec, 21	2,354,078	-3.35%
30 Sep, 21	2,435,791	-

TransCode Therapeutics (RNAZ) has 262.20K shares outstanding as of 31 Mar 23, down -24.05% compared to the previous quarter.

Institutional Ownership Trend

Date	Ownership %	Change %
31 Mar, 23	0.09%	633.44%
31 Dec, 22	0.12%	18.95%
30 Sep, 22	0.80%	123.25%
30 Jun, 22	0.80%	455.76%
31 Mar, 22	0.42%	40.26%
31 Dec, 21	1.02%	91.47%
30 Sep, 21	1.06%	-

As of 31 Mar 23, TransCode Therapeutics is held by 0.09% institutional shareholders, representing a 633.44% growth compared to 31 Dec 22.

Institutional Increased Positions Trend

Date	Increased Positions	Change %
31 Mar, 23	4	-73.33%
31 Dec, 22	15	-
30 Sep, 22	-	-100.00%
30 Jun, 22	4	-
31 Mar, 22	4	-50.00%
31 Dec, 21	8	-50.00%
30 Sep, 21	16	-

4 institutional shareholders have increased their position in RNAZ stock as of 31 Mar 23 compared to 15 in the previous quarter (a -73.33% decrease).

Institutional Reduced Positions Trend

Date	Reduced Positions	Change %
31 Mar, 23	3	-
31 Dec, 22	-	-100.00%
30 Sep, 22	3	50.00%
30 Jun, 22	2	-50.00%
31 Mar, 22	4	300.00%
31 Dec, 21	1	-
30 Sep, 21	-	-

3 institutional shareholders have reduced their position in RNAZ stock as of 31 Mar 23 compared to - in the previous quarter (a 0.00% increase).

All Institutional Ownership Trend Data

Date	Holdings	Change %	Shares Outstanding	Change %	Ownership %	Change %	Increased Positions	Change %	Reduced Positions	Change %
31 Mar, 23	11	-38.89%	262,198	-24.05%	0.09%	633.44%	4	-73.33%	3	-
31 Dec, 22	18	63.64%	345,210	-83.28%	0.12%	18.95%	15	-	-	-100.00%
30 Sep, 22	11	-8.33%	2,064,102	-0.99%	0.80%	123.25%	-	-100.00%	3	50.00%
30 Jun, 22	12	-	2,084,804	91.33%	0.80%	455.76%	4	-	2	-50.00%
31 Mar, 22	12	-14.29%	1,089,616	-53.71%	0.42%	40.26%	4	-50.00%	4	300.00%
31 Dec, 21	14	-12.50%	2,354,078	-3.35%	1.02%	91.47%	8	-50.00%	1	-
30 Sep, 21	16	-	2,435,791	-	1.06%	-	16	-	-	-

TransCode Therapeutics Insider Shareholders Trades

Open Market Insider Trades

Date	Name	Relation	Role	Transaction	Buy/Sell	Shares	Price	Value	Shares Held
Oct 02, 2023	Fitzgerald Thomas A	director, officer	Chief Financial Officer	P-Purchase	Buy	49,350	$0.51	$25.17K	56,318
Oct 02, 2023	Dudley Robert Michael	director, officer	Chief Executive Officer	P-Purchase	Buy	98,000	$0.51	$49.98K	180,262
Jun 22, 2023	Dudley Robert Michael	director, officer	Chief Executive Officer	P-Purchase	Buy	12,000	$2.65	$31.82K	82,262
Jun 22, 2023	Dudley Robert Michael	director, officer	Chief Executive Officer	P-Purchase	Buy	6,607	$2.55	$16.85K	70,262
Jun 14, 2023	Dudley Robert Michael	director, officer	Chief Executive Officer	P-Purchase	Buy	19,000	$2.76	$52.44K	61,155
Jun 13, 2023	Dudley Robert Michael	director, officer	Chief Executive Officer	P-Purchase	Buy	19,000	$2.76	$52.44K	912,114

Open Market Insider Buys

Date	Name	Relation	Role	Transaction	Buy/Sell	Shares	Price	Value	Shares Held
Oct 02, 2023	Fitzgerald Thomas A	director, officer	Chief Financial Officer	P-Purchase	Buy	49,350	$0.51	$25.17K	56,318
Oct 02, 2023	Dudley Robert Michael	director, officer	Chief Executive Officer	P-Purchase	Buy	98,000	$0.51	$49.98K	180,262
Jun 22, 2023	Dudley Robert Michael	director, officer	Chief Executive Officer	P-Purchase	Buy	12,000	$2.65	$31.82K	82,262
Jun 22, 2023	Dudley Robert Michael	director, officer	Chief Executive Officer	P-Purchase	Buy	6,607	$2.55	$16.85K	70,262
Jun 14, 2023	Dudley Robert Michael	director, officer	Chief Executive Officer	P-Purchase	Buy	19,000	$2.76	$52.44K	61,155
Jun 13, 2023	Dudley Robert Michael	director, officer	Chief Executive Officer	P-Purchase	Buy	19,000	$2.76	$52.44K	912,114

Insider Sells

Date	Name	Relation	Role	Transaction	Buy/Sell	Shares	Price	Value	Shares Held	Source

All Insider Owners Trades

Date	Name	Relation	Role	Transaction	Buy/Sell	Shares	Price	Value	Shares Held
Jun 18, 2024	Marquet Magda	director	-	A-Award	Buy	70,000	$1.20	$84.00K	70,000
Jun 18, 2024	Manting Erik	director	-	A-Award	Buy	70,000	$1.20	$84.00K	70,000
Jun 18, 2024	Fitzgerald Thomas A	director, officer	Interim CEO, CFO	A-Award	Buy	650,000	$1.20	$780.00K	650,000
Jun 18, 2024	Calais Philippe	director	-	A-Award	Buy	70,000	$1.20	$84.00K	70,000
Oct 02, 2023	Fitzgerald Thomas A	director, officer	Chief Financial Officer	P-Purchase	Buy	49,350	$0.51	$25.17K	56,318
Oct 02, 2023	Dudley Robert Michael	director, officer	Chief Executive Officer	P-Purchase	Buy	98,000	$0.51	$49.98K	180,262
Jun 22, 2023	Dudley Robert Michael	director, officer	Chief Executive Officer	P-Purchase	Buy	12,000	$2.65	$31.82K	82,262
Jun 22, 2023	Dudley Robert Michael	director, officer	Chief Executive Officer	P-Purchase	Buy	6,607	$2.55	$16.85K	70,262
Jun 14, 2023	Dudley Robert Michael	director, officer	Chief Executive Officer	P-Purchase	Buy	19,000	$2.76	$52.44K	61,155
Jun 13, 2023	Dudley Robert Michael	director, officer	Chief Executive Officer	P-Purchase	Buy	19,000	$2.76	$52.44K	912,114
May 19, 2023	Manting Erik	director	-	A-Award	Buy	45,000	$0.28	$12.75K	45,000
May 19, 2023	Marquet Magda	director	-	A-Award	Buy	45,000	$0.28	$12.75K	45,000
May 19, 2023	Fitzgerald Thomas A	director, officer	Chief Financial Officer	A-Award	Buy	300,000	$0.28	$85.02K	300,000
May 19, 2023	Dudley Robert Michael	director, officer	Chief Executive Officer	A-Award	Buy	735,000	$0.28	$208.30K	735,000
May 19, 2023	Calais Philippe	director	-	A-Award	Buy	45,000	$0.28	$12.75K	45,000
May 10, 2023	Manting Erik	director	-	A-Award	Buy	9,500	$0.30	$2.84K	9,500
May 10, 2023	Marquet Magda	director	-	A-Award	Buy	9,500	$0.30	$2.84K	9,500
May 10, 2023	Calais Philippe	director	-	A-Award	Buy	9,500	$0.30	$2.84K	9,500
Dec 14, 2022	Fitzgerald Thomas A	officer	Chief Financial Officer	A-Award	Buy	100,000	-	-	100,000
Dec 14, 2022	Dudley Robert Michael	officer	Chief Executive Officer	A-Award	Buy	135,000	-	-	135,000

The last insider buy of RNAZ was made by Fitzgerald Thomas A on Oct 02 2023, buying 49,350 shares at $0.51 per share (worth $25.17K).

TransCode Therapeutics Insider Ownership Trends

All Insider Trades Trend

Date	Buy	Sell	Buy/Sell Ratio
Q2 2023	12	-	-
Q4 2022	3	-	-
Q3 2022	1	-	-
Q2 2022	5	-	-
Q1 2022	4	-	-
Q3 2021	-	8	-

12 total buy trades, and 0 total sell trades (buy/sell ratio of 0%) were made by TransCode Therapeutics's insiders, as of Q2 2023.

Open Market Insider Trades Trend

Date	Buy	Sell	Buy/Sell Ratio
Q2 2023	4	-	-
Q4 2022	-	-	-
Q3 2022	1	-	-
Q2 2022	2	-	-
Q1 2022	-	-	-
Q3 2021	-	-	-

As of Q2 2023, Insider owners conducted 4 open market buy trades and 0 open market sell trades of TransCode Therapeutics's stocks.

TransCode Therapeutics Peer Ownership

Ticker	Company
ZVSA	ZyVersa Therapeutics, Inc.
CNSP	CNS Pharmaceuticals, Inc.
ONCR	Oncorus, Inc.
XBIO	Xenetic Biosciences, Inc.
NEXI	NexImmune, Inc.
PHIO	Phio Pharmaceuticals Corp.
REVB	Revelation Biosciences, Inc.
LABP	Landos Biopharma, Inc.
EFTR	eFFECTOR Therapeutics, Inc.
KOD	Kodiak Sciences Inc.
EYEN	Eyenovia, Inc.
IMMX	Immix Biopharma, Inc.
SONN	Sonnet BioTherapeutics Holdings, Inc.
CGTX	Cognition Therapeutics, Inc.
ZURA	Zura Bio Limited

RNAZ Ownership FAQ

Who Owns TransCode Therapeutics?

TransCode Therapeutics is owned by institutional shareholders (0.09%), insiders (0.05%), and public (99.86%). The largest institutional shareholder of TransCode Therapeutics is WELLS FARGO & COMPANY/MN (0% of total shares) and the top mutual fund owner is VANGUARD INDEX FUNDS (0.00% of total shares).

Who are the major institutional shareholders of TransCode Therapeutics?

TransCode Therapeutics's major institutional shareholders are WELLS FARGO & COMPANY/MN, STATE STREET CORP, GOLDMAN SACHS GROUP INC, SHEETS SMITH WEALTH MANAGEMENT, and TWO SIGMA INVESTMENTS, LP. The top five shareholders own together 0% of the company's share outstanding.

How many TransCode Therapeutics shareholders are there?

As of Mar 2023, there are 11 institutional shareholders of TransCode Therapeutics.

What percentage of TransCode Therapeutics is owned by WELLS FARGO & COMPANY/MN?

WELLS FARGO & COMPANY/MN owns 0 shares of TransCode Therapeutics, representing 0% of the company's total shares outstanding, valued at $0 (as of Jun 2023).

What percentage of TransCode Therapeutics is owned by STATE STREET CORP?

As of Jun 2023, STATE STREET CORP holds 0 shares of TransCode Therapeutics (RNAZ), compromising 0% of the company, valued at $0.

What percentage of TransCode Therapeutics is owned by GOLDMAN SACHS GROUP INC?

GOLDMAN SACHS GROUP INC is the third largest holder of TransCode Therapeutics. The company owns 0 of the company's shares outstanding (worth $0).